# PT-141 Effects, Benefits & Side Effects — What the Record Shows > PT-141 (bremelanotide) effects: the cited benefits the trials measured, the nausea-led side-effect profile, and the safety cautions on the label. Off-label vs. approved framing throughout. What the studies measured, what people report, and who the label says should be careful. ## The short version PT-141 effects come in two flavors: what controlled studies measured, and what people online report. They are not the same thing, and this page keeps them apart. The measured benefit: in approved use (low sexual desire causing distress in premenopausal women), desire goes up a little and distress goes down a little versus a dummy injection [3]. "A little" is honest — the effect is statistically real but small, and some researchers question how meaningful it is [3]. The measured downside: nausea, often. Around 40% of women in long-term use felt it [4]. Flushing and headache are next [4]. Repeated frequent dosing can darken skin and gums [7]. The label warns about a short-lived blood-pressure rise [7]. Nothing here is a dose recommendation. ## What the studies measured In the pivotal RECONNECT trials (n=1267 premenopausal women with HSDD), bremelanotide 1.75 mg as-needed raised the desire score (FSFI-desire +0.35, P<.001) and lowered desire-related distress (FSDS-DAO item 13 -0.33, P<.001) over 24 weeks versus placebo [3]. Both coprimary endpoints met. Both effect sizes small. The 52-week open-label extension (684 women) showed no new safety signals and sustained desire improvement [4]. Tolerability, not efficacy, was the limiting factor. A 2022 fMRI study (31 women) gave mechanistic backing: MC4R agonism increased desire for up to 24 hours and changed how the brain processed erotic stimuli [5]. A 2026 systematic review and meta-analysis pooled the trials and found bremelanotide improved total FSFI plus the desire and arousal subscales [15]. ## PT-141 for men Off-label and investigational — state it plainly. PT-141 is not FDA-approved for men [7]. The male evidence is early-phase: systemic administration produced dose-dependent erectile activity in men with erectile dysfunction in dose-ranging work [1], and early intranasal studies reported a statistically significant erectile response above ~7 mg [7]. A 2025 narrative review positions PT-141 as a centrally acting investigational ED option and stresses that large trials are still needed [14]. One 2008 erectile-dysfunction salvage study carries a 2023 Expression of Concern and should be treated as disputed [7]. ## PT-141 for women This is the one approved column. Bremelanotide is indicated for acquired, generalized HSDD in premenopausal women [7][10]. That is the population the Phase 3 trials enrolled and the only population the FDA cleared [3][7]. It is distinct from off-label transdermal testosterone used in postmenopausal women [10]. Postmenopausal use of PT-141 is not approved [7]. The benefit in the approved group is the modest desire/distress shift described above [3]. ## What people report These are effects reported by the research-use community — **anecdotal, not clinical evidence**, and not verified by controlled trials. No doses are attached, and these reports do not establish that PT-141 does anything. Reported upsides cluster around increased sexual desire and arousal appearing hours after a dose. Reported downsides echo the trial data closely: nausea is the most-mentioned complaint, sometimes strong enough to overshadow any benefit, alongside flushing, headache, and a flushed or "hot" feeling. Some report transient nausea fading with repeated exposure; others report it does not. None of that is a clinical finding — the controlled-trial profile above is the evidence. ## PT-141 side effects From the controlled record. Over long-term use the most common drug-related adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. Nausea is the principal tolerability issue and a notable driver of discontinuation [4]. These are cited trial findings, not anecdotes. ## Safety & cautions Each caution below is cited. **Blood pressure.** The label documents a transient blood-pressure increase and contraindicates use in uncontrolled hypertension or known cardiovascular disease [7]. This is a labeled warning, not a theoretical one. **Nausea.** Common (~40% over long-term use) and a leading reason people stop [4]. **Hyperpigmentation.** Darkening of the face, gums, and breasts is reported with repeated frequent dosing, attributed to MC1R activation (a peripheral melanocortin receptor governing pigment) [7]. **Appetite circuits.** MC4R is also expressed in appetite circuits; caloric-intake and body-weight effects seen in high-frequency Phase 1 dosing are a relevant pharmacological consideration — theoretical for ordinary use, and not an approved indication [7]. **Unregulated material.** A "PT-141 research chemical" sits outside the approval framework, with no oversight of identity, purity, or concentration [7]. This page recommends no dose and is not medical advice. --- A magenta-circuit terminal reading of the PT-141 (bremelanotide) record — the one approved indication printed first, the label dose and trial figures echoed back verbatim, the off-label and unregulated-research-chemical lines traced in amber, and the community field reports fenced off as unverified; no clinic wired behind the console and nothing here dosed, sourced, prescribed, or sold.